Jerajani, Kaushal
11  results:
Search for persons X
?
2

Multi-dose Formulation Development for a Quadrivalent Human..:

Sharma, Nitya ; Jerajani, Kaushal ; Wan, Ying...
Journal of Pharmaceutical Sciences.  112 (2023)  2 - p. 458-470 , 2023
 
?
3

Multi-Dose Formulation Development for a Quadrivalent Human..:

Jerajani, Kaushal ; Wan, Ying ; Kumru, Ozan S....
Journal of Pharmaceutical Sciences.  112 (2023)  2 - p. 446-457 , 2023
 
?
4

Analytical and Preformulation Characterization Studies of H..:

Jerajani, Kaushal ; Wan, Ying ; Hickey, John M....
Journal of Pharmaceutical Sciences.  111 (2022)  11 - p. 2983-2997 , 2022
 
?
7

Multi-dose Formulation Development for a Quadrivalent Human..:

Sharma, Nitya ; Jerajani, Kaushal ; Wan, Ying...
This work describes Part 2 of multi-dose formulation development of a Human Papillomavirus (HPV) Virus-Like Particles (VLPs) containing vaccine (see Part 1 in companion paper). Storage stability studies with candidate multi-dose formulations containing individual or combinations of seven different antimicrobial preservatives (APs) were performed with quadrivalent HPV VLP (6, 11, 16, 18) antigens adsorbed to aluminum-salt adjuvant (Alhydrogel®). Real-time (up to two years, 2-8°C) and accelerated (months at 25 and 40°C) stability studies identified eight lead candidates as measured by antigen stability (competitive ELISA employing conformational serotype-specific mAbs), antimicrobial effectiveness (modified European Pharmacopeia assay), total protein content (SDS-PAGE), and AP concentration (RP-UHPLC). The AH-adsorbed HPV18 VLP component was most sensitive to AP-induced destabilization. Optimal quadrivalent antigen storage stability while maintaining antimicro....  , 2022
 
1-11